Congenital absence of bile ducts is a rare and serious liver condition affecting newborns, where the tiny tubes that carry digestive fluid from the liver become blocked or fail to develop properly. Without timely treatment, this condition can lead to severe liver damage within the first months of life, making early recognition and specialized care critical for a baby’s survival and long-term health.

What Treatment Options Are Available for This Condition?

When a baby is diagnosed with congenital absence of bile ducts, the main goal of treatment is to restore the flow of bile, which is a digestive fluid made by the liver. Bile normally travels through small tubes called bile ducts from the liver to the intestines, where it helps digest food and carries away waste products. When these ducts are blocked or absent, bile gets trapped in the liver, causing damage that can progress rapidly. Treatment must be started as soon as possible to prevent the liver from becoming permanently scarred and to give the baby the best chance of survival.

The approach to treating this condition depends on the timing of diagnosis, how much liver damage has already occurred, and the specific anatomy of the baby’s bile duct system. There are two main treatment pathways: surgical procedures to restore bile flow and, if those procedures are not successful, liver transplantation. Both treatment options have been refined over many years and are now offered at specialized pediatric hospitals around the world.

It is important to understand that this condition is not inherited and does not run in families. Researchers believe it may be caused by a combination of factors, including viral infections during pregnancy, problems with the immune system, or issues during the baby’s development before birth. However, the exact cause remains unknown in most cases, which is why ongoing research continues to explore potential triggers and risk factors.

Standard Surgical Treatment

The primary standard treatment for congenital absence of bile ducts is a surgical procedure called the Kasai procedure, also known as hepatoportoenterostomy. This operation was first described by Dr. Morio Kasai in the 1950s and has since become the gold standard for initial surgical correction of this condition. The goal of the Kasai procedure is to create a new pathway for bile to flow from the liver to the intestines, bypassing the blocked or absent bile ducts.

During the Kasai procedure, the surgeon removes the damaged or blocked bile ducts outside the liver and connects a loop of the baby’s small intestine directly to the liver at the place where bile normally drains. This loop is called a Roux-en-Y loop. By creating this new connection, bile can drain from the liver into the intestine, reducing the buildup of bile that causes liver damage. The surgery is complex and delicate because the bile ducts in a newborn are extremely tiny, measuring less than one millimeter in width—thinner than a piece of spaghetti.

The timing of the Kasai procedure is crucial. Studies have shown that when the surgery is performed before the baby is 45 to 60 days old, the chances of success are significantly higher. At this early stage, liver damage may still be limited, and restoring bile flow can prevent further scarring. If the surgery is delayed beyond this window, the liver may develop cirrhosis, which is permanent scarring that prevents the liver from working properly. For this reason, any baby who has yellowing of the skin and eyes (jaundice) lasting beyond two weeks after birth should be evaluated urgently by a specialist.

The success rate of the Kasai procedure varies. In many cases, the surgery successfully restores bile flow, and the baby’s jaundice improves. However, complications can occur. Some babies develop infections of the bile ducts, a condition called cholangitis, which requires treatment with antibiotics. Others may experience continued scarring of the liver despite the surgery. Even when the Kasai procedure is initially successful, many children will eventually need a liver transplant as they grow older, because the underlying liver damage may continue to progress over time.

After the Kasai procedure, babies require close monitoring and long-term follow-up care. They are typically given medications to help bile flow more easily, such as ursodeoxycholic acid, which is a type of bile acid that helps protect the liver and improve bile drainage. Fat-soluble vitamins (vitamins A, D, E, and K) are also given as supplements because the baby’s ability to absorb these vitamins from food is reduced when bile flow is impaired. These vitamins are essential for normal growth and development, and their deficiency can lead to problems such as bleeding disorders, bone weakness, and vision problems.

Liver Transplantation

Liver transplantation is the definitive treatment for babies with congenital absence of bile ducts when the Kasai procedure fails to restore bile flow or when liver damage progresses despite surgery. Congenital absence of bile ducts is the most common reason why babies and young children need liver transplants in the United States and many other countries. Advances in transplant surgery and immunosuppressive medications over the past several decades have dramatically improved survival rates for children receiving liver transplants.

A liver transplant involves removing the damaged liver and replacing it with a healthy liver from a donor. The donor liver can come from a deceased person or, in some cases, from a living donor who donates a portion of their liver. Living donor transplants are often preferred for children because a parent or close relative can donate part of their liver, which then grows to full size in both the donor and the recipient over time. This option can also reduce the waiting time for a transplant, which is important because babies with severe liver damage may not survive a long wait on the transplant list.

Before a liver transplant can be performed, the medical team conducts extensive evaluation to ensure the baby is healthy enough for surgery and to identify the best donor match. Blood tests are done to check liver function, clotting ability, and overall health. Imaging tests such as ultrasound or CT scans may be used to assess the size and condition of the liver and surrounding organs. The baby’s nutritional status is also carefully monitored and optimized, as good nutrition is essential for successful surgery and recovery.

The liver transplant surgery itself is a major operation that can take many hours. After the transplant, the baby must take medications called immunosuppressants for the rest of their life to prevent the body’s immune system from rejecting the new liver. Common immunosuppressant drugs include tacrolimus and prednisone. These medications must be taken exactly as prescribed, and regular blood tests are needed to monitor drug levels and liver function. While immunosuppressants are highly effective at preventing rejection, they also increase the risk of infections and other complications, so children who have had liver transplants require lifelong medical follow-up.

The long-term outlook for children who receive liver transplants for congenital absence of bile ducts has improved significantly in recent years. With specialized care and proper management, 80% to 90% of babies with this condition now survive to adulthood. Many children go on to lead active, healthy lives, attending school, participating in sports, and eventually pursuing careers and families of their own. However, they do face ongoing challenges, including the need for daily medications, regular medical checkups, and monitoring for complications such as organ rejection or side effects from immunosuppressive drugs.

Supportive and Nutritional Care

In addition to surgery and transplantation, supportive care plays a critical role in managing congenital absence of bile ducts. Because bile is essential for digesting fats, babies with this condition often have difficulty absorbing nutrients from food. This can lead to poor weight gain, malnutrition, and deficiencies of fat-soluble vitamins. To address these problems, babies are given special formulas that contain medium-chain triglycerides (MCTs), which are a type of fat that can be absorbed more easily even when bile flow is reduced.

Vitamin supplementation is essential. Babies with blocked bile ducts cannot absorb vitamins A, D, E, and K from their diet, so these vitamins must be given as supplements, often in water-soluble forms that are easier to absorb. Vitamin K is particularly important because it is needed for normal blood clotting, and deficiency can lead to serious bleeding problems. Regular blood tests are done to monitor vitamin levels and adjust supplement doses as needed.

Babies with congenital absence of bile ducts are also at risk for developing complications related to liver damage. One common problem is portal hypertension, which is high blood pressure in the veins that carry blood to the liver. Portal hypertension can cause fluid to accumulate in the abdomen (a condition called ascites) and can lead to enlarged veins in the esophagus (esophageal varices) that may bleed. Medications such as diuretics may be prescribed to reduce fluid buildup, and in some cases, procedures may be needed to treat or prevent bleeding from varices.

Itching is another common and distressing symptom for babies and children with bile duct problems. The buildup of bile acids in the skin causes intense itching that can interfere with sleep and quality of life. Medications such as cholestyramine, which binds bile acids in the intestine, or rifampin, an antibiotic that can help reduce itching, may be prescribed. Keeping the skin moisturized and avoiding overheating can also help reduce itching.

Treatment in Clinical Trials

Researchers around the world are working to develop new treatments for congenital absence of bile ducts that could improve outcomes and potentially reduce the need for liver transplantation. Clinical trials are studies in which new drugs, procedures, or other interventions are tested to see if they are safe and effective. Participation in clinical trials is voluntary, and families are given detailed information about the potential benefits and risks before deciding whether to enroll their child.

One area of research focuses on understanding the causes of congenital absence of bile ducts. Scientists are studying the genes and molecular pathways involved in bile duct development to identify potential targets for new therapies. Some studies have suggested that certain genetic mutations may play a role in the condition, particularly in cases where babies also have other birth defects affecting the heart, spleen, or intestines. Advanced genetic testing techniques are being used to analyze tissue samples from affected babies to look for genetic changes that could explain why the bile ducts failed to develop properly.

Another area of active research involves trying to prevent or slow down the liver damage that occurs after bile ducts become blocked. Inflammation and scarring of the liver are major problems in this condition, so researchers are testing medications that could reduce inflammation or protect liver cells from damage. For example, some clinical trials are investigating the use of corticosteroids, which are powerful anti-inflammatory drugs, given either at the time of the Kasai procedure or in the weeks afterward, to see if they can improve bile flow and reduce liver scarring. However, results from these studies have been mixed, and corticosteroids are not yet considered standard treatment.

Some researchers are also exploring the potential of stem cell therapy for treating liver damage in babies with congenital absence of bile ducts. Stem cells are special cells that can develop into different types of tissue and may have the ability to repair damaged organs. In laboratory studies and early clinical trials, stem cells have shown promise in reducing liver scarring and improving liver function. However, this research is still in the early stages, and much more work is needed before stem cell therapy can be considered a routine treatment option.

Clinical trials are also investigating new approaches to improve the success of liver transplantation. For example, some studies are testing new combinations of immunosuppressive drugs that might be more effective at preventing organ rejection while causing fewer side effects. Other trials are looking at ways to improve the long-term health of children after transplantation, such as strategies to prevent complications like kidney damage, high blood pressure, or delayed growth.

In recent years, researchers have used advanced techniques such as transcriptomics, which involves studying thousands of genes at once, to analyze diseased bile duct tissue from babies with this condition. This research is helping scientists understand which genes are turned on or off in damaged bile ducts, which could lead to the identification of new drug targets. For example, if researchers find that a specific gene is abnormally active and is causing inflammation, they might be able to develop a drug that blocks that gene’s activity.

Some clinical trials are also focused on improving early diagnosis of congenital absence of bile ducts. Researchers are testing newborn screening programs that measure levels of direct bilirubin or conjugated bilirubin in a baby’s blood during the first few weeks of life. High levels of direct bilirubin can be an early warning sign of bile duct problems. By identifying affected babies earlier, doctors hope to perform the Kasai procedure at a younger age, when the chances of success are highest. Some studies have shown that universal newborn screening for high bilirubin levels can significantly increase the number of babies diagnosed before serious liver damage occurs.

Most common treatment methods

• Kasai Procedure (Hepatoportoenterostomy)
  • Surgical procedure that removes blocked bile ducts and connects the liver directly to the intestine using a loop of small bowel called a Roux-en-Y loop
  • Most successful when performed before 45 to 60 days of age, before severe liver scarring develops
  • May restore bile flow and improve symptoms such as jaundice, but many patients eventually require liver transplantation
  • Requires long-term follow-up and medications to support bile flow and prevent complications
• Liver Transplantation
  • Replacement of the damaged liver with a healthy liver from a deceased or living donor
  • Considered when the Kasai procedure fails to restore bile flow or when liver damage progresses to cirrhosis
  • Most common reason for liver transplants in infants and young children
  • Requires lifelong immunosuppressive medications such as tacrolimus and prednisone to prevent organ rejection
  • With modern care, 80% to 90% of children survive to adulthood after transplantation
• Nutritional Support
  • Special formulas containing medium-chain triglycerides (MCTs) to improve fat absorption when bile flow is reduced
  • Supplementation with fat-soluble vitamins (A, D, E, and K) to prevent deficiencies that can cause bleeding, bone problems, and vision issues
  • Medications such as ursodeoxycholic acid to help bile flow more easily and protect the liver
  • Regular monitoring of growth, nutrition, and vitamin levels through blood tests
• Management of Complications
  • Antibiotics to treat or prevent cholangitis (infection of the bile ducts), which can occur after the Kasai procedure
  • Diuretics to reduce fluid buildup in the abdomen (ascites) caused by portal hypertension
  • Medications such as cholestyramine or rifampin to reduce severe itching caused by bile acid buildup in the skin
  • Procedures to treat bleeding from enlarged veins (esophageal varices) if portal hypertension develops